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Abstract
Background: CD133 (Prominin) is widely used as a marker for the identification and isolation of neural precursor cells from
normal brain or tumor tissue. However, the assumption that CD133 is expressed constitutively in neural precursor cells has
not been examined.
Methodology/Principal Findings: In this study, we demonstrate that CD133 and a second marker CD15 are expressed
heterogeneously in uniformly undifferentiated human neural stem (NS) cell cultures. After fractionation by flow cytometry,
clonogenic tripotent cells are found in populations negative or positive for either marker. We further show that CD133 is
down-regulated at the mRNA level in cells lacking CD133 immunoreactivity. Cell cycle profiling reveals that CD133 negative
cells largely reside in G1/G0, while CD133 positive cells are predominantly in S, G2, or M phase. A similar pattern is apparent
in mouse NS cell lines. Compared to mouse NS cells, however, human NS cell cultures harbour an increased proportion of
CD133 negative cells and display a longer doubling time. This may in part reflect a sub-population of slow- or non-cycling
cells amongst human NS cells because we find that around 5% of cells do not take up BrdU over a 14-day labelling period.
Non-proliferating NS cells remain undifferentiated and at least some of them are capable of re-entry into the cell cycle and
subsequent continuous expansion.
Conclusions: The finding that a significant fraction of clonogenic neural stem cells lack the established markers CD133 and
CD15, and that some of these cells may be dormant or slow-cycling, has implications for approaches to identify and isolate
neural stem cells and brain cancer stem cells. Our data also suggest the possibility that CD133 may be specifically down-
regulated during G0/G1, and this should be considered when this marker is used to identify and isolate other tissue and
cancer stem cells.
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Introduction
Findings of continuous neurogenesis in the mammal central
nervous system (CNS) have raised great interest in neural stem and
progenitor cells in both basic and applied neurobiology [1–5].
However, interogation of neural stem cells is hampered by the lack
of specific markers. Proteins such as Nestin, Musashi, Sox2, and
glial fibrillary acidic protein (GFAP) are expressed in neural
precursor cells [6–9], but they are also expressed by other cell
types. More importantly, intracellular markers cannot be used for
prospective stem cell isolation, although in mice this problem may
be circumvented by creating transgenic reporter animals [10–13].
Recent studies have indicated that certain cell surface markers can
be used to locate and enrich neural precursor cells. Capela and
Temple (2002) isolated proliferative and neurogenic precursor cells
from adult mouse subventricular zone (SVZ) by harvesting cells
expressing LeX, a carbohydrate adhesion molecule also known as
CD15 (leucocyte cluster of differentiation 15) or SSEA-1 (stage-
specific embryonic antigen 1) [14,15]. Uchida et al. successfully
isolated neural precursor cells from human foetal tissue using an
antibody directed towards CD133 (Prominin) [16]. CD133
immunopurification was later applied by Lee et al. and Corti et
al. to isolate neurosphere forming precursor cells from mouse
foetal cerebellum and forebrain [17,18]. In each of these cases,
enriched cells expressed neural stem cell markers and were capable
of multi-lineage differentiation both in vitro and in vivo [16–18].
Interestingly, CD133 expression could also be detected in a
relatively small subpopulation of cells in brain tumours [19]. When
these CD133+ cells were isolated, they were able to proliferate,
form clonal neurospheres, and produce new tumors after serial
transplantation [20–22]. CD133 positive cells are therefore
considered as candidate cancer stem cells that maintain tumors
[23]. Nonetheless, it is not clear whether all neural stem cells or
brain cancer stem cells express CD133. Purified CD133+ or
CD15+ cells become heterogeneous in neurosphere cultures, but
this has been ascribed to differentiation [14,16–18]. However,
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the majority of slow dividing SVZ type B cells[24], considered as
adult neural stem cells. Furthermore, tumorigenic cell lines have
been derived from CD133 negative glioblastoma cells [25].
We previously reported the establishment of adherent mouse
and human neural stem (NS) cell lines that are capable of clonal
expansion and tri-potent differentiation [26,27]. Unlike neuro-
sphere cultures, NS cell lines are purified undifferentiated neural
stem cell populations and therefore allow direct investigation of the
stem cells. In this manuscript, we examine CD133 and CD15
expression in NS cell lines and the association with potency and
cell cycle phase.
Results
Human NS cells exhibit heterogeneous CD133 and CD15
expression
To determine whether CD133 and CD15 are expressed by
human neural stem cells in culture, we performed immunostaining
on three independent human NS cell lines, CB541, CB660, and
CB660sp [26]. CB541 and CB660 cell lines were derived from
human foetal brain, and CB660sp was derived from human foetal
spinal cord. All cell lines are maintained in monolayer culture
conditions described previously [26]. In the presence of epidermal
growth factor (EGF) and fibroblast growth factor 2 (FGF2), these
cells remain undifferentiated and express a range of neural
precursor and radial glia markers including Nestin, Sox2, Pax6,
Vimentin, brain lipid binding protein (BLBP) and 3CB2 (Figure 1A
and 1B, and data not shown). These markers are expressed
relatively homogeneously throughout the NS cell population. In
contrast, immunostaining of live or fixed cells reveals that human
NS cells display heterogeneous expression of both CD133 and
CD15 (Figure 1A–1C). Flow cytometry analysis confirmed this
heterogeneity and showed that, on average, 3162% of human NS
cells express CD133 (CD133+/CD156) and 1062% express
CD15 (CD1336/CD15+). The majority (6862%) of cells do not
express either marker, while 862% express both (Figure 1D and
Table 1).
To investigate whether the variation in CD133 and CD15
expression might represent different cell populations in culture, we
fractionated NS cells into CD133
2/CD15
2, CD133+/CD15
2,
Figure 1. Human NS cells express CD133 and CD15 heterogeneously. Human NS cells homogeneously express the neural precursor marker
Nestin (A and B, red), but exhibit heterogeneous CD133 (A, green) and CD15 (A, green) expression. Live cell staining (C) and subsequent flow
cytometry analysis (D) reveal four sub-populations of human NS cells: CD133+/CD15
2, CD133+/CD15+, CD133
2/CD15+, and CD133
2/CD15
2. The
proportions of each cell population are listed in Table 1.
doi:10.1371/journal.pone.0005498.g001
Table 1. Human NS cell lines display heterogeneous CD133
and CD15 expression (%)
CD133+ CD133+ CD133
2 CD133
2
CD15
2 CD15+ CD15+ CD15
2
CB541 21.73 11.03 1.67 65.57
CB660 21.94 7.27 2.46 68.33
CB660SP 22.47 7.18 1.20 69.15
Average 22.0560.38 8.4962.20 1.7860.64 67.6861.88
n=750,000
doi:10.1371/journal.pone.0005498.t001
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PLoS ONE | www.plosone.org 2 May 2009 | Volume 4 | Issue 5 | e5498Figure 2. CD133 and CD15 expression varies in human NS cells but is not linked to stem cell potency. Human NS cells were flow sorted
into four populations using the gates illustrated in (A) and then cultured in NS cell expansion conditions. One week later, each sorted cell population
exhibited heterogeneous CD133 and CD15 expression (B). Four weeks later, all four cell populations displayed near-indistinguishable CD133 and
CD15 distributions (B). Clonal cultures could also be derived from all four purified cell populations after cell sorting. The cloned cells retained
tripotent, being able to generate neurons (Tuj1+) (C), astrocytes (high level GFAP with flattened morphology) (D), and oligodendrocytes (O4+) (E).
doi:10.1371/journal.pone.0005498.g002
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2/CD15+ populations by flow
cytometry using the gates illustrated in Figure 2A (purity $95%).
Sorted cells were then cultured in self-renewal conditions in the
presence of EGF and FGF2. Each population proliferated and
after one week, we found all had re-acquired heterogeneous
CD133 and CD15 expression (Figure 2B). When cultures were
expanded for another 4 weeks, all four cell populations displayed
similar CD133 and CD15 distribution (Figure 2B). In order to
verify that CD133 and CD15 expression can switch within cell
populations, we performed clonal analysis by depositing single
human NS cells from each purified cell fraction. Colonies could be
generated from single cells from all four NS cell populations.
Immunostaining after 6 weeks expansion shows all NS cell clones
exhibit heterogeneous CD133 and CD15 expression (data not
shown). When further cultured, these colonies could generate
clonal cell lines that were able to produce all three CNS cell types
under appropriate differentiation conditions (Figure 2C–2E). The
percentages of immunopositive neurons, oligodendrocytes, and
astrocytes generated were 40–45%, 1–2%, and over 98%
respectively. These values were similar between clones and in
the same range as our previous report [26].
The above findings establish that clonogenic human NS cells do
not express CD133 or CD15 constitutively. However, we noticed
that colony formation efficiency did vary in relation to cell surface
marker expression (Table 2). Surprisingly, the lowest frequency
was from the double positive CD133+/CD15+ cells, only 3 out of
192 of which generated colonies. From 192 single CD133+/
CD15
2 and CD133
2/CD15+ cells, 8 and 4 cells respectively
produced colonies. Unexpectedly, the highest efficiency of 15%
was from the CD133
2/CD15
2 population. These colonies were
morphologically undifferentiated and indistinguishable from the
parental human NS cell cultures.
CD133 expression is regulated at the mRNA level in
human NS cells
The above data suggest that CD133 and CD15 expression
varies in human NS cell cultures and absence of these markers
does not reflect loss of stem cell potency. To investigate whether
CD133 expression in NS cells is regulated at the level of
transcription or protein shedding [28], we collected mRNA from
purified CD133
+/hi and CD133
2/lo human NS cells. RT-PCR
and real-time PCR indicate that prominin/CD133 mRNA
expression is down-regulated approximately 30 fold in CD133
2/lo
cells compared to CD133
+/hi cells (Figure 3Aa and 3Ab).
Since the expression of some cell surface markers is related to
cell density or cell cycle phase [29], we investigated whether
CD133 and CD15 expression may be regulated by these factors.
We first investigated human NS cells cultured at different densities.
We plated human NS cells at 4610
3,4 610
4, and 4610
5 cells per
cm
2 respectively and expanded them in the same medium.
Immunostaining and flow cytometry analysis performed 2 days
later indicated that cells plated at low density exhibited similar
heterogeneous distribution of CD133 and CD15 as high density
cultures (Table 3).
We next examined cell cycle correlation using Hoechst staining
[30]. Based on 1.7610
5 scored events, flow cytometry analysis
indicates that 65% of human NS cells are in G1/G0, 18% in S
phase, and 17% in G2/M phase. We found 91% of CD133
2/lo
cells have 2N DNA content, constituting 75% of all scored G1/G0
cells (Figure 3Ba–3Bd). Only 31% of CD133
+/hi cells were in G1/
G0, while 69% were in S, G2, or M (Figure 3Ba–3Bd). In contrast,
both CD15
+/hi and CD15
2/lo NS cells are distributed evenly
throughout the cell cycle (Figure 3Be–3Bh). To test the indication
that CD133 may be preferentially down-regulated in cells in G0/
G1 phase, we purified CD133
+/hi and CD133
2/lo cells (puri-
ty$95% and 98% respectively) (Figure 3Ca) and applied
propidium iodide (PI) staining after fixation [31,32]. Flow
cytometry analysis indicated that over 88% of CD133
2/lo cells
were in G1/G0, whereas approximately 65% of CD133
+/hi cells
had .2N DNA content (Figure 3Cb and 3Cc).
CD133 is also expressed heterogeneously by mouse NS
cells
To investigate whether other mammalian neural stem cells
express CD133 in a similar pattern, we applied similar staining
and flow cytometry analysis to mouse NS cells [27]. Mouse NS cell
lines derived either from embryonic stem (ES) cells (CGR8-NS cell
line) or foetal cortex (Cor-1 cell line) exhibit heterogeneous CD133
expression (Figure 4A). On average, approximately 4661% of
mouse NS cells were immunopositive for CD133, and 5461% of
cells negative. Since Hoechst33342 shows considerable toxicity
towards mouse NS cells, we applied an alternative dye, VybrantH
DyeCycle
TM Violet, to analyze cell cycle. Based on 5610
5 scored
events, flow cytometry analysis indicated that 59% of mouse NS
cells reside in G1/G0, 23% in S phase, and 18% in G2/M phase.
Similar to observations in human NS cell cultures, CD133
2/lo
cells were mostly 2N, while just over half (51%) of the CD133
+/hi
cells have greater than 2N DNA content (Figure 4B and 4C).
Human NS cell cultures may harbour slow-cycling or
dormant stem cells
The doubling time of human NS cell cultures (2–3 days) is much
longer than that of mouse NS cells (,24 hours) [26,27]. Human
NS cells also exhibit a higher percentage of CD133 negative cells
that are mostly in G1/G0. Since human NS cell cultures do not
express differentiation markers under expansion conditions [26],
the longer doubling time is unlikely to be due to NS cell
differentiation into non-proliferative cell lineages. We speculated
that a fraction of human NS cells may spontaneously withdraw
from the cell cycle (entering G0) which could contribute to a
prolonged doubling time. We performed immunostaining against
Ki67, a nuclear protein expressed by proliferating cells in all cell
cycle phases. We found 79.6862.40% of mouse NS cells expressed
Ki67, but only 53.4866.62% of human NS cells exhibited Ki67
immunoreactivity under identical culture conditions (Figure 5A).
Bromo-deoxyuridine (BrdU) incorporation experiments revealed
that mouse NS cell cultures contained a higher percentage of
BrdU labelled cells at all checked time points, reaching a plateau
close to 100% after ,3 days incubation (Figure 5B and 5C). In
contrast, the fraction of BrdU+ human NS cells began to level off
at ,95% after 4 days incubation (Figure 5B and 5D). This suggests
that up to 5% of human NS cells may be slow-dividing or non-
dividing, although they have not differentiated into neurons or
glia.
Table 2. Colony formation efficiency of single deposited
human NS cells
CD133+ CD133+ CD133
2 CD133
2
CD15
2 CD15+ CD15+ CD15
2
4.2% 1.6% 2.1% 15.0%
n= 192
doi:10.1371/journal.pone.0005498.t002
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5498Figure 3. CD133 expression is regulated at the mRNA level and is reduced in G0/G1 phase. (A) RT-PCR (Aa) and real-time PCR (Ab)
indicate that the expression of CD133 mRNA in CD133
2/lo human NS cells is approximately 30 fold lower in CD133
+/hi cells. CD133
2/lo and CD133
+/hi
NS cells were purified by cell sorting using the gate illustrated in Ba below. (B) Cell cycle analysis of human NS cells stained with Hoechst 33342, anti-
CD133- Neural Stem Cells
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dormant or slow-dividing cells, we attempted double staining with
Hoechst and Pyronin Y [33,34]. However, this combination
proved extremely toxic and over 99% of human and mouse NS
cells died after staining. We therefore applied the antimitotic drug
cytosine-b-d-arabinofuranoside (Ara-c, 2%) [35,36] to eliminate
dividing human NS cells. Approximately 5% of human NS cells
remained viable after 5 days Ara-c treatment. Immunostaining
showed these cells retained Nestin and Sox2 expression, but they
were not positive for CD133, Ki67, or Caspase-3 (Figure 6A and
6B, and data not shown). Upon re-plating without Ara-c and
culturing for 10 days in EGF and FGF, approximately 15% of cells
displayed Ki67 expression and 8.7% expressed CD133 (Figure 6C
and 6D). When further cultured, these cells expanded continuously
and could differentiate as other NS cells (data not shown).
Discussion
Cell surface markers CD133 and CD15 have been recognized
as neural stem cell markers and have been applied to enrich for
neural precursor cells from various sources [14,16–18,37].
However, to our knowledge, purified CD133 or CD15 expressing
neural precursor cells have not been maintained as homogeneous
cell populations in vitro. In neurosphere cultures this is obscured
because neural precursor cells spontaneously differentiate into glial
lineages [38–40]. By analyzing purified human NS cell lines [26],
we find CD133 and CD15 are only expressed by a subpopulation
of neural stem cells. We demonstrated that single CD133 and/or
CD15 negative cells could generate clonal and tripotent neural
stem cell lines. The two cell surface markers were invariably
expressed heterogeneously in proliferating cultures. Therefore
cultured neural stem cells are not constitutively CD133 or CD15
positive. This could be related to the observation that CD133
expression appears linked to cell cycle phase in NS cells. CD133
negative cells are disproportionately represented in G0/G1.
Recently, cell cycle dependent variation in CD133 expression
has been described for colon cancer and melanoma cell lines [41].
These authors also find that CD133 levels are down-regulated in
G0-G1, suggesting that this may be a generic feature.
In our adherent culture conditions CD133 negative human NS
cells exhibited higher colony formation efficiency than CD133
positive cells. Previous analyses using primary human foetal CNS
tissue have indicated that few or even no neurospheres could be
derived from CD133 negative cell populations [16]. However,
primary tissues contain overwhelming numbers of differentiated
cells that are CD133 negative. Therefore CD133 sorting will give
a major enrichment even if only capturing a fraction of the stem
cells. It is also possible that CD133 negative stem cells may not
initiate colony formation in suspension culture, even though they
do so efficiently when adherent. The higher cloning efficiency we
observed for CD133 negative versus CD133 positive cells might be
because G0/G1 cells are intrinsically more clonogenic, or they
may be less fragile and more resistant to flow sorting compared
cells in S, G2, or M phase. Alternatively they may have some other
feature that resists stress-induced differentiation or promotes
attachment.
Interestingly, although human and mouse NS cells are cultured
under identical conditions, human NS cell cultures harbour fewer
CD133+ cells and exhibit a longer doubling time than mouse
counterparts. Ki67 staining and BrdU incorporation experiments
indicated that a subpopulation of human NS cells may withdraw
from the cell cycle. The fraction of non-cycling human NS cells,
estimated from BrdU incorporation (Figure 5B) is around 5%
whereas this is less than 0.2% in mouse NS cell cultures. These
non-cycling cells do not show features of differentiation or
senescence, and retain precursor markers suggesting they could
be dormant stem cells. To investigate further we applied Ara-c, an
antimitotic drug, to eliminate dividing cells. Approximately 5% of
human NS cells remained viable. These cells retained Nestin and
Sox2 expression but did not express CD133 or Ki67. Parallel
BrdU labelling confirmed they were not dividing. Crucially
however, a proportion of these cells resumed proliferation after
the antimitotic drug was removed. This strongly suggests that
human NS cells in culture can suspend proliferation but retain the
capacity to re-enter the cell cycle.
A major interest in neural stem cell biology is the relationship
with brain tumor cells [42,43 [44]]. CD133 has been successfully
applied to isolate brain tumor initiating cells, also called cancer
stem cells [19,20]. It was found that malignant brain tumors have
a higher CD133 index than low-grade tumors [19]. Based on the
present observations, however, this does not necessarily indicate an
increased frequency of stem cells but may reflect a higher
proliferative index in the stem cell compartment. Indeed we have
found that glioblastoma stem cells also exhibit heterogeneous
CD133 and CD15 expression in vitro [44], similar to the profile
observed in human NS cells. If CD133 expression in brain cancer
stem cells is regulated in a cell cycle dependent fashion, extra
caution must be taken when this marker is used to define tumour
stem cells. This would be particularly significant if CD133 is not
expressed by quiescent brain cancer stem cells.
In conclusion, our data demonstrate that mammalian neural
stem cells are not constitutively CD133 or CD15 positive, and
that down-regulation of CD133 protein and mRNA correlates
with an enrichment of cells in G0-G1 phase of the cell cycle.
CD133-APC, and anti-CD15-FITC. Analysis gates were set as illustrated in Ba and Be. The CD133
+/hi, CD133
2/lo, CD15
+/hi, and CD15
2/lo cells are colored
red, green, pink, and blue respectively (Ba-h). Ungated cells are colored black. The cell cycle profile of the entire population is illustrated by dashed
lines in Bb and Bf. The majority of CD133
2/lo (green) cells were in G1/G0 phase of the cell cycle (Bb and Bc), whereas over half of the CD133
+/hi (red)
cells were in S, G2, or M phase (Bb and Bd). Although human NS cells express CD15 heterogeneously (Be), the CD15+
/hi (pink) and CD15
2/lo (blue) cell
populations exhibited similar cell cycle profiles, consistent with the whole cell population (Bf-Bh). (C) To test the indication that CD133 may be
preferentially down-regulated in cells in G0/G1 phase, we purified CD133
+/hi and CD133
2/lo cells using the gates illustrated in Ca and applied PI
staining after fixation. Flow cytometry analysis indicated that the majority of CD133
2/lo cells were in G1/G0 (Cb), whereas over half of CD133
+/hi cells
had .2N DNA content (Cc).
doi:10.1371/journal.pone.0005498.g003
Table 3. Human NS cells plated at different density exhibit
similar CD133 and CD15 distribution (%)
CD133+ CD133+ CD133
2 CD133
2
CD15
2 CD15+ CD15+ CD15
2
4610
3 cells/
cm
2
19.71 10.04 1.89 68.36
4610
4 cells/
cm
2
19.09 8.23 2.56 70.12
4610
5 cells/
cm
2
21.37 6.19 1.19 71.25
n=200,000
doi:10.1371/journal.pone.0005498.t003
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expression in slow-cycling or dormant neural stem cells. It will be
informative to investigate whether CD133 expression is similarly
down-regulated in G0/G1 in adult neural stem cells in vivo. The
mechanisms and regulation of NS cell dormancy are also of
interest for future study.
Figure 4. Mouse NS cells express CD133 heterogeneously. Live mouse NS cells exhibit heterogeneous CD133 expression (A). Flow cytometry
indicated that 50% of CD133
2/lo cells (green) were in G1/G0 phase, whereas over half (51%) of the CD133+
/hi cells (red) were in S, G2, or M phase (B,
C).
doi:10.1371/journal.pone.0005498.g004
Figure 5. Human NS cell cultures propagate more slowly than mouse counterparts. Compared to mouse NS cell cultures, human NS cell
cultures exhibit a lower percentage of Ki67 expressing cells under the same expansion conditions (A). Over 99% of mouse NS cells incorporated BrdU
after 5 days incubation (B, C). Approximately 5% of human NS cells remained BrdU negative after prolonged incubation (B, D). Yellow arrows in
Figure 5D indicate BrdU negative human NS cells after 10 days incubation.
doi:10.1371/journal.pone.0005498.g005
CD133- Neural Stem Cells
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Cell culture
The derivation of human and mouse NS cell lines is described in
[26] and [27]. Established human and mouse NS cell lines are
cultured on laminin (10 mg/L, Sigma) coated dishes (Iwaki) in
expansion medium comprising RHB-A medium (Stem Cell
Sciences Ltd., UK), recombinant mouse EGF (10 ng/ml,
Peprotech), and recombinant human FGF-2 (10 ng/ml, Pepro-
tech). Expansion medium was changed every 2 days. Cells were
detached and split 1:2 to 1:3 using Accutase (Sigma) once cultures
became confluent. Clonal NS cell lines were generated by
deposition of single cells into laminin coated 96-well plates using
a Dako Cytomation MoFlo cell sorter. The presence of single cells
was checked under a bright field microscope after sorting. Culture
medium was renewed by 50% change every 3 days for clonal
expansion. Clones were passaged after 4 weeks. Differentiation
protocols for generating neurons, astrocytes, and oligodendrocytes
from NS cells are described in [26] and [27].
Immunostaining
For intracellular staining, cells were fixed with 4% PFA for
15 minutes at room temperature followed by 30 minutes incuba-
tion with BLOCK solution. Each 100 ml BLOCK solution
contained 97 ml PBS, 3 ml serum, and 0.1% Triton-X100. Cells
were then incubated with primary antibodies for 2 hours at room
temperature or overnight at 4uC. We used Alexa-Fluor secondary
conjugates (Invitrogen) and DAPI (Sigma) to visualize the staining.
Primary antibodies were used at the following dilutions: Nestin
(1:500; R&D Systems), Sox2 (1:400; Chemicon), GFAP (1:300;
Millipore), Tuj1 (1:200, Covance), 3CB2 (1:20, DSHB), BLBP
(1:500, Abcam), Vimentin (1:20, DSHB), and Ki67 (1:250, Lab
Vision).
To stain live cells, cultured cells were incubated with primary
antibody in serum-free expansion medium for 15 minutes at room
temperatures followed by 3 washes with medium. Staining was
visualized by incubation with Alexa-Fluor secondary conjugates
(Invitrogen) for 10 minutes at room temperatures. Primary
antibodies were used at the following dilutions: anti-human
CD133 (1:10, Miltenyi Biotec), anti-mouse CD133 (1:5,
eBioscience), anti-human CD15 (1:10, Miltenyi Biotec), and anti-
O4 (1:100, R&D Systems). Live stained cells could subsequently be
fixed and stained with further antibodies.
For BrdU assays, NS cells were plated into 12-well plates with
expansion medium and were incubated at 37uC overnight for
recovery. Cells were then expanded in the presence of 10 mM
BrdU (Sigma). Cells were fixed in 4% paraformaldehyde at
different time points. After fixation, we added 500 ml of 2M HCl
into each well and left at room temperature for one hour. Cells
were then stained with anti-BrdU antibody (Sigma) using protocols
described above.
Semi-quantitative and real-time RT–PCR
We used RNeasy kit (Qiagen) to extract total RNA and
Superscript III (Invitrogen) to prepare cDNA. cDNA concentra-
tions were determined and normalized by NanoDrop-1000
Figure 6. Human NS cell cultures harbour slow-cycling or dormant cells. Approximately 5% of human NS cells remained viable after 5 days
exposure to the antimitotic drug Ara-c. The viable cells retained Nestin and Sox2 expression but did not express Ki67 or CD133 (A, B). When these
cells were re-plated into medium without Ara-c for 10 days, approximately 14.6% of cells expressed Ki67 and 8.7% expressed CD133 (C, D). Yellow
arrows in (C) indicate Ki67 positive cells.
doi:10.1371/journal.pone.0005498.g006
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markers except b-actin for 25 cycles (denaturing for 40 s at 94uC;
annealing for 40 s at 56uC, extension for 60 s at 72uC). PCR
products were resolved on 1.5% agarose gel. Real-time PCR was
carried out using a LightCycler (Roche). Primers were designed
using MIT Primer3 software as follows: b-actin forward primer 59-
GTC TTC CCC TCC ATC GTG-39, b-actin reverse primer 59-
AGG TGT GGT GCC AGA TTT TC-39, CD133 forward
primer 59-CAG AGT ACA ACG CCA AAC CA-39, CD133
reverse primer 59-AAA TCA CGA TGA GGG TCA GC-39.
Flow cytometry and cell sorting
Single-cell suspensions were stained with antibodies against
human CD133 (1:10, APC conjugated, Miltenyi Biotec), mouse
CD133 (1:5, APC conjugated, eBioscience), and human CD15
(1:10, FITC conjugated, Miltenyi Biotec). Dead cells were
excluded using forward and side scatter as well as the vital dye
Topro-3 (Molecular Probes) or 7AAD (BD). Typically 1 million
cells were stained in an eppendorf tube. Antibodies were added
into serum-free medium and incubated in the dark for 15 minutes
at room temperatures. Cells were then centrifuged and washed 3
times in medium prior to analysis or sorting. Flow cytometry
analysis was carried out on a CyAn ADP analyzer (Beckman). Cell
sorting was performed using a MoFlo sorter (Dako Cytomation).
Matched isotype antibodies were applied in parallel as controls.
Cell cycle was analyzed using two methods. For live NS cells, a
single cell suspension containing approximately 1 million cells was
incubated with 0.5 mg Hoechst 33342 (Invitrogen) or 0.5 mg
Vybrant DyeCycle Violet (Invitrogen) at 37uC for 30 minutes in
1 ml medium. Alternatively, the cell suspension was fixed in 70%
ethanol at 220uC for 15 minutes. Cells were then centrifuged and
incubated in 5 ml PBS at room temperature for 15 minutes.
Finally, approximately 1 million cells were transferred to PBS
containing 0.5 mg/ml propidium iodide (Invitrogen) and 1 mg/ml
RNAse (Sigma). Cell cycle analysis was carried out on a CyAn
ADP analyzer (Beckman) and using Flowjo software (Tree Star,
Inc). CD133/CD15 staining was performed on live cells before
Hoechst and propidium iodide staining in cases of triple staining.
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